AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01894815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
Study NCT01894815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS + Placebo Pill
Description: This group receives sham tDCS and placebo pill.
Study NCT00776685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Description: Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
Study NCT04295265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone message
Description: Receive daily whatsapp/ SMS message to remind the drug intake
Study NCT04739865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Open label
Study NCT01966432 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referral to Treatment
Description: Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
Study NCT00870493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg daily oral
Study NCT00870493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren 300 mg daily oral
Study NCT00870493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: starch tablet, 300 mg/day
Study NCT00870493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: starch tablet, 300 mg/day
Study NCT00408681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium carbonate
Description: Given orally
Study NCT00408681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00863187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: b cell depletion
Study NCT02062931 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Preparation and Injection
Description: Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.~Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue.
Study NCT02610283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QPI-1002
Description: IV injection
Study NCT02610283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic saline
Study NCT02764840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isokinetic dynamometer
Description: In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
Study NCT02764840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastic tube
Description: In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
Study NCT02156700 — intervention group
Intervention type: PROCEDURE
Intervention: Shear wave elastography
Description: Measurement of tumor stiffness by Shear wave elastography - SWE™
Study NCT02534337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX
Description: gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
Study NCT02534337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4
Description: Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
Study NCT02732158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Products
Description: a sachet containing AN777and amino acids; a carotenoid capsule
Study NCT03972371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ProVee Urethral Expander System
Description: The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.
Study NCT01268397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction and internal fixation with a volar plate
Description: flexor carpi radialis approach, open reduction, fixed-angle volar plate, plaster cast 2 weeks at the surgeon's discretion
Study NCT01268397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed reduction and plaster treatment
Description: closed reduction, below elbow plaster cast, semicircular for 5 week
Study NCT02792777 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: Patients will be engaged in open-ended, semi-structured qualitative interviews, which will be performed one-on-one either in person or over the phone (depending on the healthcare setting that they are recruited from). Qualitative interviews will be audio recorded, with the patient's permission, transcribed, de-identified and entered into NVivo software for coding and analysis.
Study NCT02792777 — intervention group
Intervention type: OTHER
Intervention: Concept Mapping (CM)
Description: The CM process consists of 3 steps that take place over 3 sessions:~Step 1: Generation of Ideas- Participants brainstorm and generate responses to the focus statement. Once the group agrees that no new statements are being generated, the list of statements is reviewed within the group.~Step 2: Structuring of Statements- Each participant is given a set of sort cards and asked to sort the statements into piles. Participants then rate each idea regarding importance. Research staff enters this information into the CM software.~Concept Systems Global Software generates point maps using a technique that detects underlying similarities/differences between statements. The CM software then uses hierarchical cluster analysis to draw boundaries around the point map to create conceptual clusters.~Step 3: Interpretation- The CM group revises the concept map. Participants review the cluster names suggested by the software and decide upon final naming of each cluster as a group.
Study NCT03497962 — intervention group
Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.
Study NCT03497962 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Broncho-alveolar lavage to obtain alveolar macrophages
Study NCT04301453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Scent
Description: Mothers will wear a breast pad during their visit. The breast pad will be placed in the hats of infants for 24 hours.
Study NCT03731715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
Study NCT01966432 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Intervention
Description: Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
Study NCT03556696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI-REMI-loop
Description: experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
Study NCT03556696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil pK/pD target administration device
Description: standard practice, remifentanil administration using Minto's pK/pD model
Study NCT03556696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.
Study NCT03556696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.
Study NCT03556696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range
Study NCT03556696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range
Study NCT03556696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ANI monitor
Description: ANI (Analgesia Nociception Index) value is used in the std_practice arm for guidance of the remifentanil Ce target
Study NCT02255838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscope reusable (Storz 8402 2x)
Description: Bronchoscopy and alveolar lavage
Study NCT02255838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscope disposable (aScope 4)
Description: Bronchoscopy and alveolar lavage
Study NCT04230577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real LED Intervention
Description: A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).
Study NCT04230577 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Real LED Intervention
Description: A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).
Study NCT04230577 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LED Intervention
Description: A series of Sham at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, Vielight Neuro Alpha Head Frame Device (with intranasal) with Sham LEDs that emit no photons. Sham and Real Devices look and feel identical.
Study NCT01032278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
Study NCT01032278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
Study NCT00647023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 1000 mg metformin x 2 daily during 8 months
Study NCT02599012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject®
Description: intravenous Ferinject 1000mg injection
Study NCT01745055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 (tofacitinib)
Description: CP-690,550 30 mg q12h for 5 days
Study NCT01745055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: individual dose of methotrexate (stably dosed)
Study NCT00802477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of autologous blood products.
Description: Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
Study NCT01111188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.~(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg
Study NCT01111188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.~(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2
Study NCT00682838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management
Description: Self-management
Study NCT00682838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemonitored care
Description: Telemonitored care
Study NCT00682838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitored care
Description: Telemonitored care
Study NCT00802477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Modified Radical Mastectomy
Description: Mastectomy per standard procedure without the application of autologous blood products.
Study NCT01377467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (Prolia)
Description: 60 mg s.c. injection at baseline and after 6 months
Study NCT02628730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI using ThermoCool® SmartTouch® Catheter
Description: PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
Study NCT02628730 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RFA ablation data comparison
Description: Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
Study NCT00513630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Study NCT00513630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01696214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone 250 mg/salmeterol 50 mg
Description: Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
Study NCT01696214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast 10mg
Description: Participants will be assigned to montelukast once a day for 24 weeks.
Study NCT01696214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theophylline 400 mg
Description: Participants will be assigned to theophylline once a day for 24 weeks
Study NCT01696214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ipratropium
Description: Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
Study NCT00465569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cow's milk powder
Description: Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
Study NCT00465569 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02648230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: St. Jude Medical Pressure Wire
Description: FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time
Study NCT02648230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACIST Navvus Microcatheter
Description: FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
Study NCT03013127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy.
Study NCT03315091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - AZD1775 administered under fasted conditions
Description: Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
Study NCT03315091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - AZD1775 administered under fed conditions.
Description: Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor.
Study NCT00584740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: 10 mg/kg
Study NCT00584740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AIN457
Study NCT02856893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 60 or 40 mg daily until progression
Study NCT02856893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib 60 or 40 mg daily until progression
Study NCT02856893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg daily until progression
Study NCT02856893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib 250mg daily until progression
Study NCT03965273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full TP
Description: The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Community and Social Norms Change Component; iv) Facilitated sessions with mothers' groups and (separate) fathers' groups; v) 2-days intensive facilitated workshop with selected religious leaders and influential people; vi) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vii) Trainings of girls, boys and parents with special interest in activism.
Study NCT03965273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light TP
Description: The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Facilitated sessions with mothers' groups and (separate) fathers' groups; iv) 2-days intensive facilitated workshop with selected religious leaders and influential people; v) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vi) Trainings of girls, boys and parents with special interest in activism.
Study NCT00964080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBP-426/Leucovorin/5-FU
Description: MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
Study NCT00105053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute-Prostate Cancer Vaccine
Description: Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
Study NCT02514473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809
Study NCT02514473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02514473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Study NCT01358279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: A constant current of 2 mA intensity applied for 20 min over C3 or C4
Study NCT02311101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Given intravesically